Batimastat-coated stent enters pivotal trial:
This article was originally published in Clinica
Executive Summary
Biocompatibles International and British Biotech have begun a pivotal European clinical trial of a batimastat-coated coronary stent, which the firms are developing jointly. The BRILLIANT II trial, a 400-patient, multicentre, double-blind, randomised study, is evaluating Biocompatibles' BiodivYsio stent coated with British Biotech's drug as a means of reducing restenosis in patients who have undergone angioplasty. Data from the trial will be used to support a European marking application. The two companies this month announced a joint US trial of the drug-coated stent (see Clinica No 990, p 17).